Antony A. Riley is CFO at Forte Biosciences, Inc. (FBRX). They have made 5 open-market trades across 2 companies since 2018, most recently 2026-07-01.
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
4 open-market purchases totalling $631K since 2018, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| FBRX | 42,600 | $3.3M |
| KRYS | 9,050 | $2.9M |
| Total | $6.1M |
Shares reported on the most recent Form 4, priced at the 2026-07-06 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| FBRX | BUY | 2025-12-30 | 2026-01-02 | $26.33 | $255K | +28.5% | +38.1% | +2.0% |
| FBRX | BUY | 2024-11-21 | 2024-11-22 | $5.55 | $250K | +55.3% | +20.3% | -32.3% |
| FBRX | SELL | 2021-09-07 | 2021-09-07 | $4.24 | $197K | -13.9% | -33.7% | -46.4% |
| FBRX | BUY | 2020-06-26 | 2020-06-30 | $14.40 | $96K | -0.1% | +44.9% | +240.4% |
| KRYS | BUY | 2018-05-22 | 2018-05-24 | $10.75 | $30K | +21.7% | +41.9% | +59.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.